Editas Medicine (EDIT) Profit After Tax (2015 - 2025)

Editas Medicine (EDIT) has reported Profit After Tax for 11 consecutive years, with -$25.1 million the latest figure, recorded in Q3 2025.

• In Q3 2025, Profit After Tax rose 59.58% year-over-year to -$25.1 million; the TTM figure through Sep 2025 stood at -$199.8 million (up 5.1% YoY), while the FY2024 annual figure was -$237.1 million, down 54.74% from the prior year.
• Profit After Tax advanced to -$25.1 million in Q3 2025 per EDIT's latest filing, from -$53.2 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$18.9 million in Q4 2023 and bottomed at -$76.1 million in Q1 2025.
• Historically, Profit After Tax has averaged -$50.4 million across 5 years, with a median of -$53.2 million in 2025.
• Annual changes were most pronounced in 2021 — Profit After Tax sank 599.83% — and 2023, when it jumped 68.93%.
• Editas Medicine's Profit After Tax stood at -$41.4 million in 2021, then plunged by 46.58% to -$60.7 million in 2022, then surged by 68.93% to -$18.9 million in 2023, then tumbled by 140.52% to -$45.4 million in 2024, then surged by 44.67% to -$25.1 million in 2025.
• Business Quant data shows EDIT's Profit After Tax at -$25.1 million in Q3 2025, -$53.2 million in Q2 2025, and -$76.1 million in Q1 2025.